The Prevalence of Immunologic Injury in Renal Allograft Recipients with De Novo Proteinuria by Sun, Qiquan et al.
The Prevalence of Immunologic Injury in Renal Allograft
Recipients with De Novo Proteinuria
Qiquan Sun*, Song Jiang, Xue Li, Xianghua Huang, Kenan Xie, Dongrui Cheng, Jinsong Chen, Shuming Ji,
Jiqiu Wen, Mingchao Zhang, Caihong Zeng, Zhihong Liu
Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China
Abstract
Post-transplant proteinuria is a common complication after renal transplantation; it is associated with reduced graft and
recipient survival. However, the prevalence of histological causes has been reported with considerable variation. A clinico-
pathological re-evaluation of post-transplant proteinuria is necessary, especially after dismissal of the term ‘‘chronic allograft
nephropathy,’’ which had been considered to be an important cause of proteinuria. Moreover, urinary protein can promote
interstitial inflammation in native kidney, whether this occurs in renal allograft remains unknown. Factors that affect the
graft outcome in patients with proteinuria also remain unclear. Here we collected 98 cases of renal allograft recipients who
developed proteinuria after transplant, histological features were characterized using Banff scoring system. Cox
proportional hazard regression models were used for graft survival predictors. We found that transplant glomerulopathy
was the leading (40.8%) cause of post-transplant proteinuria. Immunological causes, including transplant glomerulopathy,
acute rejection, and chronic rejection accounted for the majority of all pathological causes of proteinuria. Nevertheless,
almost all patients that developed proteinuria had immunological lesions in the graft, especially for interstitial inflammation.
Intraglomerular C3 deposition was unexpectedly correlated with the severity of proteinuria. Moreover, the severity of
interstitial inflammation was an independent risk factor for graft loss, while high level of hemoglobin was a protective factor
for graft survival. This study revealed a predominance of immunological parameters in renal allografts with post-transplant
proteinuria. These parameters not only correlate with the severity of proteinuria, but also with the outcome of the graft.
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Introduction
Post-transplant proteinuria is a common complication after
renal transplantation. It is found in 25% of renal allograft
recipients at 6 months [1], and nearly 50% at 1 year after
transplantation [2]. The development of proteinuria is associated
with reduced graft survival, independent of other risk factors,
including glomerular pathology, graft function, and acute rejection
[2,3]. If urine protein is at the level of nephrotic syndrome, half of
the patients will lose their graft within 2 years [4]. Even low-grade
proteinuria is correlated with decreased graft survival [5,6].
Nevertheless, proteinuria is also an independent risk factor for
both cardiovascular and non-cardiovascular death [7,8]. As
a result, post-transplant proteinuria is becoming a significant
barrier to both renal allograft and recipient survival.
The pathogenesis of proteinuria is complex. It can originate
from both the native kidney and the allograft [9,10], and may be
caused by both glomerular damage and interstitial/tubular injury.
Although this has been known for some time [11,12], the overall
clinico-histological features of patients with post-transplant pro-
teinuria are far from clarified. The prevalence of histological
causes reported by different centers has been quite different
[1,2,4,8,12]. ‘‘Chronic allograft nephropathy,’’ which has been
defunct as a term since 2005 [13] had also been counted as an
important cause of proteinuria [2,4,9]. Urine protein can promote
interstitial inflammation [14] in patients with kidney diseases,
however, whether post-transplant proteinuria shares the same
mechanism in inducing allograft injury need to be clarified.
Moreover, factors that affect the graft outcome in patients with
proteinuria also remain unclear. Thus, a clinico-pathological
reevaluation of post-transplant proteinuria under the current Banff
classification is necessary.
This study was performed to evaluate the overall clinical
features and histological spectrum of post-transplant proteinuria.
We unexpectedly revealed a high prevalence of immunological
parameters in these patients, and moreover, these factors were
correlated with the severity and outcome of the grafts. These
findings question current strategies of managing post-transplant
proteinuria.
Materials and Methods
Patients
Patients were selected from renal transplant recipients de-
veloping proteinuria from Jan. 2005 to Dec. 2008 at the Research
Institute of Nephrology, Jinling Hospital, Nanjing University
School of Medicine. Proteinuria is defined as urine protein over
0.4 g/d measured in 24-h collections by colorimetric methods.
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de novo proteinuria .0.4 g/d, (3) aged 18–60 years old, (4) having
received baseline renal biopsies and index renal biopsy when
proteinuria emerged, and (5) under follow-up for no less than 1
year. Patients who received sirolimus treatment were excluded
because the incidence of proteinuria depends on the proportion of
patients receiving this medicine. Patients in whom proteinuria
emerged immediately after transplantation and declined over time
were also excluded as this may have been related to the native
kidney and have less influence on long-term graft survival.
Patients were followed at our institution, and all patients had
a thorough evaluation once per week during the first 3 months,
then once every 2 weeks until 6 months, monthly till the end of the
first year, and bi-monthly thereafter. Data were recorded using
a web-based recording system. Proteinuria was screened by urine
test strips cassette with the URISYS 2400 urinalysis analyzer
(Roche Diagnostics GmbH, Mannheim, Germany) at each visit,
and by 24-h collection at every 6 months, or whenever the
screening test was positive. The urine protein level was measured
in 24-h collections by colorimetric methods. Urine n-acetyl-b-
glucosaminidase (b-NAG) [15] and retinol binding protein (RBP)
[16,17] were used to evaluate the tubular injury. Graft function
was evaluated with estimated glomerular filtration rate (eGFR).
HLA-I, II antibody detection and lymphocytotoxic
crossmatch
IgG anti-HLA class I and class II antibodies in serum samples
were detected by flow cytometric analysis using the methods
described by Pei et al [18]. Sera with .10% reactivity for HLA
class I and/or II were considered positive for the presence of anti-
HLA antibodies. HLA-I, II antibodies were monitored pre- and
post-transplant, and whenever a renal biopsy was performed. Pre-
transplant screening for donor-specific alloantibodies was also
performed through complement-dependent lymphocytotoxicity
methods using the National Institutes of Health technique with
undiluted complement (without wash).
Renal allograft pathology
Baseline biopsies were performed in all allografts to exclude any
ongoing disease in the transplanted kidney. Diagnostic biopsies
were performed whenever proteinuria emerged. Two needle
biopsy cores were obtained from each renal allograft for
morphological study, which were then divided into two parts:
one for formalin fixation and one for quick-freezing. Hematoxylin
and eosin, periodic acid Schiff, methenamine-silver, and Masson
staining were routinely used on the formalin-fixed tissue. Fresh
frozen tissue was analyzed by immunofluorescence microscopy
using a conventional panel of antibodies against IgG, IgM, IgA,
C3, C4, C1q, and C4d. Ultrastructural study were routinely
studied using electron microscopy (EM) for all the samples. Since
2007, polyomavirus-associated nephropathy was routinely
screened using the anti-SV-40 large T antigen antibody on all
the biopsies. Histological features were scored using the latest
Banff scoring criteria [13,19,20,21] and CADI scoring [22]. All
biopsies contained at least ten glomerular and two arterial sections.
The pathology lesions are sorted into acute rejection, chronic
rejection, TG, IF/TA, and de novo or recurrent glomerular
diseases, such as IgA nephropathy, membranous nephropathy
(MN), and focal segmental glomerulosclerosis (FSGS). The
definition of the diagnosis terms were listed in table 1. Twenty
protocol biopsy samples taken over one year post transplantation
were randomized selected as controls.
Initial immunosuppression
Two primary immunosuppressive protocols were used in the
course of this study: cyclosporine A (CsA), mycophenolate mofetil
(MMF) and steroids or tacrolimus, MMF, and steroids. The main
immunosuppressive protocols were CsA+MMF+steroid during
June 2004 to June 2006, and tacrolimus+MMF+steroid since July
2006. AZA instead of MMF was also used before 2000. Induction
therapy with daclizumab or basiliximab could also be used. The
maintenance doses of tacrolimus and CsA were adjusted to target
specific trough levels: 6–12 ng/mL during the first 6 months, 4–
8 ng/mL thereafter for tacrolimus, and 150–250 ng/mL during
the first 6 months and 100–200 ng/mL thereafter for CsA.
Management of Proteinuria
Patients were given angiotensin-converting enzyme inhibitors
and/or angiotensin receptor blockers when proteinuria occurred.
For patients developing TG, the dose of MMF was increased to
1.5 g/d if the current dose was lower than 1.5 g/d. Additional
immunoadsorption was used too if there were high levels of HLA
class-I or II antibodies.
Statistics
Descriptive statistical values are expressed as means6SD.
Analyses were performed using the SPSS software (ver. 15.0;
SPSS, Chicago, IL, USA). A t-test was used for comparing means
and a chi-squared test was used for testing the significance of
categorical variables. Survival curves were estimated using the
Kaplan-Meier method, and differences were evaluated by the log-
rank test. Cox proportional hazard regression models were used to
adjust for the potential confounding effects of variables with
statistical differences between the groups to evaluate the
association between predictor variables and graft survival. A p
value of ,0.05 was considered to indicate statistical significance.
Results
Baseline Characteristics
Ninety-eight renal transplant recipients who developed pro-
teinuria were included; there were 77 males and 21 females, all
were negative for HLA-I and II antibodies before transplantation.
The emerging time of proteinuria was 4.1962.96 years (ranged
from 1months to 10 years) post transplant, and the biopsies were
performed immediately after protein emerging. As to the primary
diseases that caused renal failure, 3 were diabetic nephropathy, 3
were FSGS, 4 were IgAN, 2 were membranous nephropathy, 1
were HSPN and 1 were crescent nephritis. Two were polycystic
kidney disease. As the surveillance of kidney disease was not
performed in China, the majority of patients were found to be at
end stage renal failure with not native renal biopsies available.
Baseline characteristics are listed in Table 2. The mean level of
proteinuria was 2.262.0 g/d. A total of 34.7% of patients also
showed different degrees of hematuria.
When the biopsies were performed, 41 patients used tacroli-
mus+MMF+steroid as immunosuppressive protocols and 46
patients were on CsA+MMF+steroid. There were no differences
between the two groups on baseline characteristics such as age,
gender, emerging time of proteinuria, etc. The degree of
proteinuria were similar (2.1161.76 vs 2.2861.06 g/d,
p=0.700). The other eleven patients received CsA+Aza+steroid
as immunosuppressive protocols. In addition, those patients were
randomized matched with 20 recipients who received protocol
biopsies 6 months after the transplant surgery. There were no
differences in recipients’ age, gender, baseline immunosuppres-
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and patients with proteinuria.
Characteristics of patients with different degrees of
proteinuria
Compared with control group, post-transplant proteinuria was
correlated with higher level of serum creatinine (2.8662.36 vs
1.0660.32 mg/dL, p,0.05), cholesterol (5.4862.01 vs
3.7260.72 mmol/L, p,0.05), triglyceride (1.5660.68 vs
1.1060.36, p,0.05), and lower level of serum albumin
(34.665.4 vs 41.864.6, p,0.05).
In native kidney diseases, .3.5 g/d usually is defined as
nephritic range proteinuria, while ,1 g/d usually is tubulointer-
stitial non-neprotic proteinuria. We divide the patients into 3
groups based on the level of urine protein: urine protein .3.5 g/d,
1–3.5 g/d, and ,1 g/d. There was no difference between groups
in patient age or gender. The onset time was significantly later in
patients with high levels (.3.5 g/d) of proteinuria compared with
patients with low levels (,1.0 g/d) of proteinuria (3.4562.85 vs
5.8063.01 years, p,0.05). Higher levels of proteinuria were
correlated with lower serum albumin, higher levels of blood lipid,
and urinary NAG (u/g.cr; Figure 1).
TG was the leading cause of overall post-transplant proteinuria;
it accounted for 41% of proteinuria in all ranges, followed by
IgAN for 16%, chronic rejection (TG excluded) for 12%, and
acute rejection for 11% (Figure 2A).
For proteinuria below 1.0 g/d, TG was still the leading cause.
While acute rejection was the second most important cause of
proteinuria, it accounted for 25% of this subgroup, followed by
chronic rejection (14%). Only one (3%) patient in this group was
diagnosed as having IgAN (Figure 2B). For proteinuria between 1–
3.5 g/d, TG was also the most important lesion in histology;
however, the incidence of acute rejection decreased to 4.9%, while
the incidence of IgAN increased to 24.4% (Figure 2C). In the
group of proteinuria over 3.5 g/d, TG accounted for 47.6% of all
causes, and IgAN accounted for 19%, while no patient was
diagnosed as having acute rejection (Figure 2D).
Characteristics of patients with different pathologies
We compared the clinical characteristics of six major causes of
proteinuria (Table 3). TG was the latest lesion that could cause
proteinuria, with a diagnosis time of 5.2162.71 years post-
transplant, followed by IgAN and chronic rejection. Acute
rejection was the earliest lesion, occurring at 1.2061.31 years
post-transplant, which was significantly earlier than TG (p,0.05).
Patients in the TG group had a higher level of de novo HLA
class I and class II antibodies, especially for class II antibodies.
More than 40% patients with TG were positive for HLA class II
antibodies (over 10% in PRA). The acute rejection group had
a higher level of HLA class I antibodies, but the difference was not
statistically significant. Hematuria could be found in TG, IgAN,
and acute rejection, but seldom in chronic rejection, TA/IF, or
FSGS groups.
TG could cause different ranges of proteinuria, whereas in
IgAN group, most patients (93.4%) had proteinuria over 1 g/d,
compared with 18.2% (p,0.05) in the acute rejection group. Half
of the patients in the FSGS group had proteinuria over 3.5 g/d.
With respect to graft function, all patients in the acute rejection
and chronic rejection groups, and 92.5% in the TG group had
impaired graft function, while nearly half of the patients in the
IgAN group had normal graft function. Post-transplant proteinuria
in different groups correlated with different incidences of
hypoproteinemia and hyperlipidemia. Compared with the acute
rejection group, the TG and IgAN groups had significantly higher
incidences of hypoproteinemia (p,0.05). The acute rejection
group had the lowest serum lipid levels among the six groups.
Prevalence of immunological parameters in histology
Regardless of histological diagnosis, we found that almost all
patients (95.9%) with proteinuria suffered from one or more kinds
Table 1. Definition of the diagnosis terms.
Term Abbreviation Definition
Transplant glomerulopathy TG Pathological featured duplication of the GBMs [21], and excluding other
conditions that might result in similar histological changes, confirmed by EM.
Chronic rejection CR Including chronic active antibody-mediated rejection, chronic active T-cell
mediated rejection [19], TG was excluded considering its high prevalence
and unique histological feature.
Acute rejection AR Including acute antibody-mediated rejection, acute T-cell mediated rejection
[19]
IgA nephropathy IgAN Dominant or codominant staining with IgA in glomeruli by
immunofluorescence or immunoperoxidase [38], excluding TG.
Tubular atrophy and interstitial fibrosis TA/IF Interstitial fibrosis and tubular atrophy, with no evidence of any above
specific etiology [19]
doi:10.1371/journal.pone.0036654.t001
Table 2. Baseline characteristics of patients that developed
post-transplant proteinuria.
Parameter Value
N 98
Gender (male/female) 77 (78.6%)/21 (21.4%)
Age (years) 40.6611.8/47.5610.0
Onset of proteinuria (years post
transplantation)
4.1962.96
Peritoneal/hemodialysis before
transplantation
3/95 (3.1%/96.9%)
Post-transplant complications
Diabetes 10(10.2%)
Hepatitis 15(15.3%)
Pneumonia infection 14(14.3%)
Acute rejection 20(20.4%)
doi:10.1371/journal.pone.0036654.t002
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lesions, interstitial inflammation was the most common and could
be found in 95.9% patients with proteinuria, followed by
glomerulitis in 70.4%, C4d deposition in peritubular capillaries
in 53.1%, tubulitis in 46.9%, and intimal arteritis in 14.3%. As
a typical lesion of TG, glomerular double contours could be
detected in 43.9% patients. Only four patients (4.1%) were
negative for all immunological lesions. The incidences of above
lesions were significantly higher than the matched group of graft
receiving protocol biopsies (Figure 3). Looking into the causes of
proteinuria, there was high prevalence of interstitial inflammation
in each group. TG group has a higher incidence of tubular
atrophy than acute rejection group and a higher incidence of C4d
deposition comparing with IgAN (table 4).
Factors correlated with the grade of urine protein
We also attempted to study the grade of urine protein using
clinical and histological features. We found that the quantity of
urine protein was strongly correlated with the incidence of
intraglomerular C3 deposition (r=0.293, p=0.007), degree of
tubular atrophy (Ct, r=0.289, p=0.008), glomerular sclerosis (Cg,
r=0.238, p=0.009), and interstitial fibrosis (Ci, r=0.227,
p=0.038). In contrast, it did not correlate with patient age,
gender, degree of interstitial inflammation, C4d deposition, or
graft function at diagnosis.
Prognostic factors for graft survival
TG had a poor graft survival at 5-years post-diagnosis with
32.6%, similar to the outcome of IF/TA and non-TG chronic
rejection. The 5-year graft survival in the acute rejection group
was 46.8%. IgAN had the best 5-year graft survival of 71.1% in
this cohort (Figure 4).
We performed a Cox regression analysis, which included
clinical factors such as age, gender, onset time of proteinuria,
hematuria, NAG, serum creatinine, albumin, as well the diagnosis.
Univariable analyses revealed that eGFR, range of proteinuria,
degree of interstitial inflammation, score of vascular lesions, and
degree of tubular atrophy were all risk factors for early graft loss.
In contrast, level of serum hemoglobin and albumin, the diagnosis
of IgAN were associated with graft survival. However, multivariate
analyses revealed that only the degrees of interstitial inflammation
(Figure 5A) and tubular atrophy (Figure 5B) were independent risk
factors of graft loss, while levels of serum hemoglobin (Figure 5C)
were independent protection factors for graft survival (Table 5).
Although C4d deposition could be detected in 52 (53.1%)
patients (39 diffuse, 13 focal), we did not find correlation between
C4d deposition and graft outcome. Although TG group seemed to
be correlated with a poor graft survival, univariate analyses didn’t
show TG is independent risk factor for graft loss.
Discussion
This study outlined clinicopathological features of de novo post-
transplant proteinuria under modern immunosuppressive proto-
cols and the current Banff classification system. We revealed
a predominance of immunological parameters in patients de-
veloping de novo proteinuria after transplantation. Immunological
causes, including TG, acute rejection, and chronic rejection,
accounted for 64.3% of all causes; indeed, almost all patients who
developed proteinuria had histological immunological lesions in
the graft, especially interstitial inflammation. Moreover, intraglo-
Figure 1. Characteristics of patients with different ranges of proteinuria. *, P,0.05 compared with control group; **, P,0.01 compared
with control group; ***, P,0.001 compared with control group.
+,P ,0.05 compared with urinary protein,1 g/d group;
++,P ,0.01 compared with
urinary protein,1 g/d group;
+++,P ,0.001 compared with urinary protein,1 g/d group.
O,P ,0.05 compared with urinary protein 1–3.5 g/d group;
OO,P ,0.01 compared with urinary protein 1–3.5 g/d group;
OOO,P ,0.001 compared with urinary protein 1–3.5 g/d group.
doi:10.1371/journal.pone.0036654.g001
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and the severity of interstitial inflammation was an independent
risk factor for graft loss. These data suggest the involvement of
immunological factors in graft dysfunction.
Immunological causes, including TG, acute rejection, and
chronic rejection, account for the majority of post-transplant
proteinuria. Among them, TG was the leading cause, accounting
for 41% of proteinuria, covering different ranges of urine protein,
and 42.5% of them were accompanied by hematuria. TG is
regarded as a form of late antibody-mediated rejection, however,
as it has featured glomerular damage differing to chronic rejection,
we list it separately in this study. As reported [23], the TG group
had a higher level of HLA class I and class II antibodies, especially
class II antibodies. Patients with proteinuria caused by TG had
a poor outcome, with only 32.6% 5-year graft survival. The high
incidence and poor outcome of TG might account for the poor
graft outcome of post-transplant proteinuria. It is noteworthy that
the onset of proteinuria was at 5 years after transplantation in this
group. This may explain why a recent study based on biopsies
performed at 1-year post transplantation showed only a low
incidence of TG [2]. However, TG was also the leading cause of
graft loss in that group.
Another immunological entity, acute rejection, is an important
cause of early post-transplant proteinuria and is related to poor
graft survival. Proteinuria caused by acute rejection is character-
ized by early (within 1 year) occurrence and low levels (,1 g/d). It
was rarely accompanied by hypoalbuminemia and lower levels of
serum CHOL. This is likely due to the acute tubular damage
caused by rejection, because a raised NAG level had been
observed in this group. Although proteinuria caused by acute
rejection is not as heavy as IgAN, the outcome is much worse. Our
study was consistent with data reported by Halimi et al. [24], in
Figure 2. Histological causes of post-transplant proteinuria. Figures shows histological causes of proteinuria in all patients (1A), urine protein
,1 g/d (1B), between 1–3.5 g/d (1C), and over 3.5 g/d (1D). TG was the leading cause of overall post-transplant proteinuria and each subgroup,
followed by IgAN, chronic rejection (TG excluded), and acute rejection. For proteinuria below 1.0 g/d, acute rejection was the second most important
cause of proteinuria, accounting for 25% in this subgroup; only one (3%) patient was diagnosed as having IgAN. For proteinuria between 1–3.5 g/d,
the incidence of acute rejection decreased to 4.9%, while the incidence of IgAN increased to 24.4%. In proteinuria over 3.5 g/d, IgAN accounted for
19%, and no patient was diagnosed as having acute rejection. TG, transplant glomerulopathy; IgAN, IgA nephropathy; AR, acute rejection; CR, chronic
rejection; TA/IF, tubular atrophy and interstitial fibrosis; FSGS, Focal segmental glomerulosclerosis; MPGN, Membranoproliferative glomerulonephritis;
HSPN, Henoch-Scho ¨nlein purpura nephritis; DN, diabetic nephropathy; MSP, mesangial proliferative glomerulonephritis; MN, Membranous
nephropathy.
doi:10.1371/journal.pone.0036654.g002
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plantation) lower grade proteinuria and graft outcomes correlated
with episodes of acute rejection. Unfortunately, they did not
perform surveillance biopsies in their study, so it is unclear
whether there were other coexisting lesions in those grafts.
Our data reveal a high prevalence of immunological lesions in
the histology of renal allografts with de novo proteinuria. Regardless
of histological cause, almost all patients who developed proteinuria
had interstitial inflammation in the graft, which is much higher
than in the grafts without urine protein. Although it is difficult to
clarify the cause and consequence of inflammation, it is possible
that urinary protein itself could stimulate interstitial inflammation.
In native kidney, it is well known that protein overload can
stimulate proximal tubular cells to synthesize chemokines, which
may contribute to the chronic tubulointerstitial inflammation [14].
Our data suggest that this pathway maybe also exist in renal
allograft recipients, even in the era of modern immunosuppre-
sants. Anyway, this hypothesis needs to be further proved.
Never the less, interstitial inflammation was strongly correlated
with graft outcome. Our data reveal that many factors correlated
with graft outcome, including graft function (measured with
eGFR), grade of proteinuria, scores of interstitial inflammation,
Table 3. Characteristics of patients with different histologies.
TG IgAN CR AR TA/IF FSGS
(n=40) (n=15) (n=12) (n=11) (n=6) (n=4)
Basic Characteristics
Age (years) 44.7612.3 40.968.1 37.861.8 36.4611.6 44.3612.6 36.867.9
Gender (male%) 31 (77.5%) 13 (86.7%) 8 (66.7%) 8 (72.7%) 5 (83.3%) 3 (75.0%)
Diagnosis time (years post Tx) 5.2162.71 4.6162.82 4.5663.30 1.2061.31
a 3.9963.66 2.5862.10
Urine examination
Upro (g/24 h) 2.3061.94 2.4261.27 1.7362.09 1.0660.91
b 2.9863.52 3.2562.34
,1 g/24 h 13 (32.5%) 1 (6.7%)
c 5 (41.7%) 9 (81.8%)
d 3 (50.0%) 1 (25.0%)
1–3.5 g/24 h 17 (42.5%) 10 (66.7%) 6 (50.0%) 2 (18.2%)
b 2 (33.3%) 1 (25.0%)
.3.5 g/24 h 10 (25%) 4 (26.7%) 1 (8.3%) 0 (0)
e 1 (16.7%) 2 (50.0%)
Hematuria 17 (42.5%) 8 (53.3%) 1 (8.3%) 3 (27.3%) 0 (0)
f 0 (0)
NAG (u/g.cr) 29.5620.7 24.8611.2 25.967.0 35.5636.9 22.0618.3 33.5625.3
RBP (mg/L) 6.0368.28 1.662.2 18.2613.1
g 7.469.4 13.0616.0 6.968.9
Blood examination
Albumin (g/L) 33.465.6 35.064.9
# 36.364.8 38.062.5
# 34.865.4 37.064.1
$35 g/L 18 (45%) 8 (53.3%) 8 (66.7%) 10 (90.9%)
h 2 (33.3%) 3 (75.0%)
,35 g/L 22 (55%) 7 (46.7%) 4 (33.3%) 1 (9.1%)
h 4 (66.7%) 1 (25.0%)
Scr (mg/dL) 2.6961.67 2.1462.82
b 2.4461.16 4.2162.59 4.2965.10 4.5063.29
,1.24 mg/dL 3 (7.5%) 7 (46.7%)
i 0 (0) 0 (0) 1 (12.7%) 0 (0)
$1.24 mg/dL 37 (92.5%) 8 (53.3%) 12 (100%) 11 (100%) 5 (83.3%) 4 (100%)
CHOL (mmol/L) 5.3761.66 5.4061.40 5.3961.38 4.8862.50 5.9462.27 5.9661.10
TriG (mmol/L) 1.5860.72 1.4060.45 1.5060.75 1.3560.46 1.4860.28 2.2060.95
j
HLA-I antibodies 12.6617.6 3.9361.83 2.4962.08 18.2626.5 0.7 1.2
HLA II antibodies 23.62627.91 4.2963.47 2.4461.21 7.7669.64 1.3 0.3
Hemoglobin 9.6762.44 11.6762.31
k 10.1962.22 9.4862.55 10.3363.31 11.064.06
.12 g/L 6 (15.0%) 8 (53.3%) 3 (25.0%) 1 (9.1%) 1 (16.7%) 1 (25.0%)
9–12 g/L 16 (40.0%) 5 (33.3%) 7 (58.3%) 5 (45.5%) 2 (33.3%) 2 (50.0%)
6–9 g/L 15 (37.5%) 2 (13.3%) 2 (16.7%) 4 (36.4%) 3 (50%) 1 (25.0%)
,6 g/L 3 (8.1%) 0 (0) 0 (0) 1 (9.1%) 0 (0) 0 (0)
TG: transplant glomerulopathy; IgAN: IgA nephropathy; CR, chronic rejection; AR, acute rejection; TA/IF: tubular atrophy and interstitial fibrosis; Tx, transplantation;
Upro, urine protein; NAG, n-Acetyl-b-glucosaminidase; RBP, retinol binding protein; SCr, serum creatinine; CHOL, cholesterol; TriL, Triglyceride.
a,P ,0.01, AR vs. TG, IgAN, CR;
b,P ,0.05, IgAN vs. AR group;
c,p ,0.05, IgAN vs. AR, CR, and TA/IF;
d,P ,0.05, AR vs. IgAN, FSGS and TG;
e,p ,0.05, AR vs. FSGS;
f,P ,0.05, TA/IF vs. TG and IgAN;
g,P ,0.05, CR vs. TG, IgAN;
h,P ,0.05, AR vs. TG, IgAN, TA/IF;
i,P ,0.05, IgAN vs. TG, CR, AR;
j,P ,0.05, IgAN vs. FSGS, AR;
k,P ,0.05, IgAN vs. TG, AR.
doi:10.1371/journal.pone.0036654.t003
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PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e36654Figure 3. Prevalence of histological lesions related to immune activity. Most (95.9%) of the patients with proteinuria had at least one kind of
immunological lesion, based on histology. Interstitial inflammation was the most common lesion, which could be detected in 95.9% patients with
proteinuria, followed by glomerulitis in 70.4%, C4d deposition in peritubular capillaries in 53.1%, tubulitis in 46.9%, and intimal arteritis in 14.3%.
While in the control group, only few recipients have immunological lesion. *, p,0.05 comparing with control group; **, p,0.001 comparing with
control group.
doi:10.1371/journal.pone.0036654.g003
Table 4. Histologic findings of patients with different histologies.
TG IgAN CR AR TA/IF FSGS
(n=40) (n=15) (n=12) (n=11) (n=6) (n=4)
Interstitial inflammation, n (%) 37 (92.5%) 12 (80.0%) 11 (91.7%) 11 (100.0%) 5 (83.3%) 3 (75.0%)
Glomerulitis, n (%) 33 (82.5%) 11 (73.3%) 9 (75.0%) 9 (81.8%) 2 (33.3%) 3 (75.0%)
Tubulitis, n (%) 18 (45.0%) 6 (40.0%) 7 (58.3%) 10 (90.9%) 2 (33.3%) 2 (50.0%)
Tubular atrophy, n (%) 36 (90.0%)* 14 (93.3%) 10 (83.3%) 5 (45.5%) 5 (83.3%) 3 (75.0%)
Interstitial infiltrate, n (%) 37 (92.5%) 12 (80.0%) 11 (91.7%) 11 (100%) 5 (83.3%) 3 (75.0%)
Plasma cell infiltrate, n (%) 19 (47.5%) 4 (26.7%) 7 (58.3%) 5 (45.5%) 2 (33.3%) 0 (0)
Interstitial fibrosis, n (%) 33 (82.5%) 9 (60.0%) 12 (100.0%) 7 (63.6%) 4 (66.7%) 2 (50.0%)
C4d deposition 28 (70.0%)
# 4 (26.7%) 8 (66.7%) 7(63.6%) 1 (16.7%) 1 (25.0%)
Diffuse 22 (55.0%)
# 2 (13.3%) 5 (41.7%) 3 (27.3%) 0 (0) 0 (0)
Focal 6 (15.0%) 2 (13.3%) 3 (25.0%) 4(36.4%) 1 (16.7%) 1 (25.0%)
Negative 12 (30.0%)
# 11 (73.3%) 4 (33.3%) 4 (36.4%) 5 (83.3%) 3 (75.0%)
Intraglomerular C3 deposition, n (%) 22 (55.0%)* 13 (86.7%) 5 (41.7%) 1 (9.1%) 3 (50.0%) 2 (50.0%)
Diffuse 7 (17.5%)
#* 10 (66.7%) 1 (8.3%) 1 (9.1%) 2 (33.3%) 2 (50.0%)
Focal 15 (37.5%)* 3 (20.0%) 4 (33.3%) 0 (0) 1 (16.7%) 0 (0)
Negative 18 (45.0%)* 2 (13.3%) 7 (58.3%) 10 (90.9%) 3 (50.0%) 2 (50.0%)
Intimal arteritis, n (%) 3 (7.5%) 0 (0) 1 (8.3%) 2(18.2%) 0 (0) 1 (25.0%)
small vessel fibrinoid necrosis 3 (7.5%) 1 (6.7%) 1 (8.3%) 1 (9.1%) 0 (0) 0 (0)
Small vessel thrombi 3 (7.5%) 1 (6.7%) 0 (0) 1 (9.1%) 0 (0) 0 (0)
*, p,0.05 vs AR group;
#,p ,0.05 vs IgAN group.
doi:10.1371/journal.pone.0036654.t004
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and albumin. However, only degrees of interstitial inflammation
(Figure 5A) and tubular atrophy (Figure 5B) were independent risk
factors of graft loss. In contrast, levels of serum hemoglobin
(Figure 5C) were independent protective factors for graft survival.
Among risk factors, interstitial inflammation had the highest
hazard ratio. Although a high prevalence of C4d-deposition had
been noticed in this cohort, we didn’t find correlation between
C4d deposition and graft outcome, which is consistent with data
from Sis et al based on a population of TG [25].
For the first time, we report that hemoglobin is an independent
protective factor for renal allograft survival in patients who
develop de novo post-transplant proteinuria. Specifically, anemia is
an independent risk factor for graft loss. The estimated graft
survival was 44.5 months for patients without anemia, while it was
only 22.1 months for patients with hemoglobin between 6–9 g/dL
and 13.4 months for patients with hemoglobin levels below 6 g/dL
(Figure 5C). This is another important finding that may impact
clinical practice, because anemia is common in renal allograft
recipients with proteinuria and usually is believed to be related
with eGFR. This finding is consisted with data from a multicenter
clinical trial that showed complete correction of anemia reduce the
rate of progression of chronic allograft nephropathy. [26]
Evidence that the degree of interstitial inflammation and
anemia correlates with graft survival brings into question the
traditional management of proteinuria, which consists primarily of
angiotensin-converting enzyme inhibitors and/or angiotensin
receptor blockers as the first-line treatment. [27,28,29,30,31,32]
Physicians may need to consider dealing with the underlying
immunological activity and maintaining the hemoglobin at
a higher level. A renal biopsy will still be necessary to assess the
underlying histological causes to exclude non-immunological
lesions, which may be more suitable for traditional management.
Nevertheless, our data support the hypothesis that proteinuria-
induced graft loss occurs via complex mechanisms other than the
presence of glomerular disease [28].
Our study also revealed that another immunological lesion,
intraglomerular C3 deposition, correlated with the grade of
proteinuria. Cox regression analysis revealed that in addition to
histological causes and onset time, proteinuria levels also
correlated with intraglomerular C3 deposition, degree of allograft
glomerulopathy, tubular atrophy, and interstitial fibrosis. Howev-
er, it did not correlate with patient age, gender, degree of
interstitial inflammation (i0–3), C4d deposition, or graft function
at diagnosis. For the first time, we report that the degree of de novo
post-transplant proteinuria correlated with the incidence of C3
deposition. C3 deposition in glomerulus is not rare in patients
undergoing kidney diseases, and can even be detected in living
donors during nephrectomy [33]. The significance of C3 de-
position in the development of proteinuria remains to be clarified,
although it has been reported that co-deposition of C3 with C4d is
Figure 4. Graft survival for patients with different histological causes of proteinuria. IgAN has the best graft outcome, with a 5-year graft
survival of 71.1%, while graft survival was very poor in patients with TG, TA/IF, and CR. TG, transplant glomerulopathy; IgAN, IgA nephropathy; AR,
acute rejection; CR, chronic rejection; TA/IF, tubular atrophy and interstitial fibrosis; FSGS, Focal segmental glomerulosclerosis.
doi:10.1371/journal.pone.0036654.g004
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between C3 deposition and graft survival in this cohort.
Because IgAN is the most common primary glomerulonephritis
worldwide [35] and the recurrent rate is high after transplantation
[36,37], it is not surprising that renal allograft IgAN was common
in this cohort. Our data suggest that IgAN is one of the main
causes of proteinuria over 1 g/d, and is a relatively benign lesion,
which had the best 5-year graft survival in the current cohort.
Univariation analysis also showed the diagnosis of IgAN is
protecting factor for graft loss. IgAN in this group should be
regarded as de novo or recurrent, because baseline biopsies had
been performed to exclude disease derived from the donor. The
high incidence of IgAN in this group might be partly due to its
high prevalence in the general population [35]. Although the 5-
year graft looks good in this group, additional attention should be
paid to these recipients because longer term observation revealed
decreased graft survival [36].
Moreover, our study revealed that different grades of pro-
teinuria emerging at different times correlated with different
histological findings, which could explain why a different preva-
lence of histological causes had been previously reported from
different centers [1,2,4,8,12]. Low-grade (,1 g/d) proteinuria was
mostly associated with interstitial and tubular damage, such as
acute rejection, chronic rejection, and TA/IF. Glomerular
damage is likely involved in the development of high-grade
proteinuria. Our data support the hypothesis that early proteinuria
is usually correlated with acute allograft damage, such as acute
rejection. Based on these data, b-NAG and RBP are helpful
factors in distinguishing acute and chronic lesions. Acute lesions
typically manifest as higher levels of NAG and lower levels of RBP.
In contrast, chronic lesions are correlated with lower NAG and
higher RBP. Due to the exclusion of proteinuria emerging
immediately after transplantation, no acute tubular necrosis cases
were observed in this group. Overall, based on the above data, it is
Figure 5. Risk factors correlated with the graft survival in
patients with post-transplant proteinuria. Degrees of interstitial
inflammation (A) and renal tubular atrophy (B) and levels of
hemoglobin (C) were strongly correlated with graft survival. i 0–3,
mononuclear cell interstitial inflammation grade 0–3; ct 0–3, tubular
atrophy grade 0–3. [21]
doi:10.1371/journal.pone.0036654.g005
Table 5. Independent risk factors and protective factors for
transplantation kidney survival.
Variable Univariate Multivariate
HR CI P HR CI P
Interstitial
inflammation
2.772 1.859–4.134 ,0.001 2.397 1.535–3.742 ,0.001
Tubular
atrophy
2.173 1.488–3.173 ,0.001 2.270 1.546–3.334 ,0.001
Serum
hemoglobin
0.965 0.951–0.979 ,0.001 0.971 0.953–0.990 0.003
Serum
albumin
0.932 0.874–0.993 0.028
eGFR 0.953 0.934–0.972 ,0.001
Urine
protein
1.255 1.072–1.470 0.005
Intimal
arteritis
1.443 1.025–2.033 0.036
IgA
Nephropathy
0.294 0.090–0.961 0.043
doi:10.1371/journal.pone.0036654.t005
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different times and/or of different ranges would lead to different
histological findings. This is why rare TG was reported in patients
developing proteinuria 1-year after transplantation, [2] while rare
acute rejection was reported in patients with post-transplant
nephrotic syndrome. [4]
It is necessary to acknowledge the lack of native renal biopsies in
most recipients prior to transplantation, which prevented us from
making a diagnosis of recurrent or de novo renal disease. However,
in this group, excluding IgAN, only 13.3% are likely to have de novo
or recurrent glomerulonephritis. The conclusion we draw is not
limited, because we did not focus on patients with de novo or
recurrent renal disease.
Overall, our study revealed a predominance of immunological
parameters in renal allografts with post-transplant proteinuria.
These parameters not only correlate with the severity of
proteinuria, but also with the outcome of the graft. These findings
are important because they bring into question current strategies
of managing post-transplant proteinuria. Specifically, patients
might benefit from the introduction of anti-inflammatory treat-
ments.
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